B2M and plasma cell myeloma: The immunohistochemical staining of α-fetoprotein (AFP, I), a traditional tumor marker for hepatocellular carcinoma (HCC), β2 microglobulin (β2M, II), a tumor marker for some blood cell cancers such as lymphoma and multiple myelomas [39], as well as the carcinoembryonic antigen (CEA, III), the most widely used tumor marker in patients with non-small cell lung cancer [40], were significantly enhanced in organs of the HCC-bearing mouse (+ve ctrl, left panel) compared to plasma-treated mice (right panel).